The Dividend Aristocrats No One's Talking About (And Their 30+ Year Track Records)

Dividend aristocrats get plenty of attention, but most of the time the spotlight falls on the big names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), and Procter & Gamble (NYSE:PG), among others.

24/7 Wall Street • Jan 8, 2026

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease (the "Company") announced today that Sentinel Opportunity Fund I, LP (the "Fund") has closed on the acquisitions of two mission-critical commercial properties leased to Abbott Laboratories and V3 Engineering.

Accesswire • Jan 7, 2026

Abbott: Not Cheap, But Built To Compound In Uncertain Markets

Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Libre), are driving over 12% segment growth, with Diabetes Care revenues surpassing $2B and growing 17%. ABT reaffirmed 2025 organic growth guidance of 7.5%–8% and EPS of $5.12–$5.18, with consistent, low-volatility earnings growth expected through 2027.

Seeking Alpha • Jan 7, 2026

PBH or ABT: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT). But which of these two stocks is more attractive to value investors?

Zacks Investment Research • Jan 7, 2026

PBH vs. ABT: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Abbott (ABT). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Jan 6, 2026

Abbott hosts conference call for fourth-quarter earnings

ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.

PRNewsWire • Jan 5, 2026

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choices affect glucose levels,2 provides personalized meal guidance,3 and confirms glucose impact using data from Abbott's world-leading FreeStyle Libre continuous glucose monitoring (CGM) technology4 Abbott is launching Libre Assist, available at no additional cost within the Libre app,5 during CES® 2026 ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions of people living with diabetes in the U.S. better understand how the foods they eat affect their glucose levels.

PRNewsWire • Jan 5, 2026

Abbott (ABT) Rises Higher Than Market: Key Facts

In the latest trading session, Abbott (ABT) closed at $126.45, marking a +1.82% move from the previous day.

Zacks Investment Research • Jan 6, 2026

2 Healthcare Stocks to Buy in a Bear Market

Johnson & Johnson and Abbott Laboratories are diversified healthcare companies with attractive prospects. Both have raised their dividends for over 50 consecutive years.

The Motley Fool • Jan 3, 2026

Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Dec 31, 2025